IL6 and breast carcinoma: Interleukin-6 (IL-6) induces an epithelial-mesenchymal transition (EMT) phenotype in human breast cancer cells [44], and direct application of IL-6 to breast cancer cells increases proliferation in estrogen receptor-positive (ER+) cells [45].